Eastgate Biotech :: Investors

Investors

EastGate Biotech Expands Pipeline to Alzheimer’s Disease Using its Alternative Insulin Delivery Platform

November 14, 2019 by admin

EastGate Biotech Corp. announced today that it has initiated plans to expand its alternative insulin delivery portfolio to apply to the treatment of Alzheimer’s disease.

EastGate Biotech Announces Expansion and Restructuring of Joint Venture with its Partner in Pakistan

October 9, 2019 by admin

Key products to be tested, registered and marketed include Insugin for diabetes application, alternative insulin for Alzheimer’s application, and Blood Plasma Derived Products, Human Serum Albumin 20%

EastGate Biotech Receives Regulatory Approval to Initiate a Phase III 90-day clinical trial on Insugin, its liquid insulin mouth rinse solution.

September 25, 2019 by admin

The Marketing Application Approval in Pakistan will follow subject to completion of the Phase III clinical study that will include up to 200 Type 2 patients.

Eastgate Biotech Corp (OTC: ETBI) Management Interview

September 11, 2019 by admin

Eastgate’s new COO took time to discuss his role with the company, ETBI’s licensing strategy, and upcoming goals for the next few months which includes the commencement of the Phase III trial for their flagship product, Insugin.

EastGate Biotech Announces Appointment of Bill Abajian to Lead Licensing and Marketing Phase as Chief Operating Officer

September 5, 2019 by admin

WEST CALDWELL, NJ and TORONTO, ON /NEWMEDIAWIRE/ September 4, 2019/ EastGate Biotech Corp. (OTC: PINK: ETBI), a pharmaceutical company, that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of Type 2 diabetes, announced today the appointment of distinguished executive Bill Abajian to lead the licensing and marketing phase of the company as Chief Operating Officer of the company, effective August 27, 2019.